Status:
COMPLETED
Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456)
Lead Sponsor:
Organon and Co
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
Evaluate the safety of the long-term (1 year) coadministration of ezetimibe and atorvastatin in participants with hypercholesterolemia who have not reached low density lipoprotein (LDL)-cholesterol ta...
Eligibility Criteria
Inclusion
- Participants with hypercholesterolemia who satisfy the following criteria:
- Participants who have used any of the following 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (hereinafter referred to as "statins") for 4 weeks or longer before the start of the observation period and whose low density lipoprotein (LDL)-cholesterol level during the treatment had not reached lipid management target
- Age: 20 years of age or older (at the time of obtaining informed consent)
- Sex: both males and females
- Inpatient/outpatient: Out-patient
Exclusion
- Participants for whom any of the following is applicable:
- Participants whose fasted triglyceride level measured at the start of the observation period or the treatment period exceeds 500 mg/dL
- Participants with homozygous familial hypercholesterolemia
- Participants with creatine phosphokinase (CPK) \> 2x upper limit of normal (ULN) measured at the start of the observation period or the treatment period.
- Participants with serious hepatic disorder, or participants with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2x ULN measured at the start of the observation period or the treatment period.
- Participants with a history of hypersensitivity to any ingredient of ezetimibe tablets or atorvastatin tablets
- Pregnant, nursing women, women who may be pregnant, or participants wishing to be pregnant during the study.
- Participants who have discontinued use of serum lipid lowering agents for less than 4 weeks at the start of the treatment period (8 weeks in the case of probucol). (However, if the participant had taken a serum lipid lowering agent before the test conducted at the start of the observation period, a period of discontinuation of 27 days, or 55 days in the case of probucol, is allowed.)
- Participants who are using cyclosporine from after the start of the observation period
- Participants with a history of ezetimibe use
- Participants with hyperlipidemia associated with the following diseases:
- Hypothyroidism
- Obstructive gall bladder or biliary disease
- Chronic renal failure
- Pancreatitis
- Participants with hyperlipidemia associated with concomitant use of drugs having adverse effect on serum lipids, etc
- Participants who have received an investigational drug within 4 weeks of the start of the observation period
- Other participants deemed not appropriate for study entry by the investigator
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT00654095
Start Date
December 1 2007
End Date
June 1 2009
Last Update
May 21 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.